NCT03322384: A trial that was reported late by University of California, Davis
This trial has reported, although it was 271 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03322384 |
|---|---|
| Title | UCDCC#271: A Phase I/II Trial of Epacadostat (Indolamine 2,3 Dioxygenase Inhibitor), Intralesional SD101 (Toll-receptor 9 Agonist), and Radiotherapy in Patients With Advanced Solid Tumors and Lymphoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 17, 2018 |
| Completion date | Feb. 24, 2020 |
| Required reporting date | Feb. 23, 2021, midnight |
| Actual reporting date | Nov. 22, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 271 |